Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2003

View Archived Issues

Enrollment complete in phase III trial of Vivitrex in alcohol dependence

GOT trial studies methods for achieving glycemic control in diabetes

AstraZeneca seeks approval for Nexium in NSAID-associated upper GI symptoms

Zymar approved for bacterial conjunctivitis

Regeneron announces positive preliminary phase III results with Axokine

Dual CCR3 modulators/H1 antagonists and their use reported by AstraZeneca

Novel antibacterial/antiinflammatory indolicidin-derived peptides

Leo Pharma presents novel TNF-alpha and IL-1beta production inhibitors

New GABA-A modulators for anxiety and convulsions under study at Merck

Alpha7 nicotinic acetylcholine receptor agonists presented by Pharmacia

Novel NPY antagonists in Banyu development pipeline

Yissum researchers prepare and test new DNA-damaging platinum complexes

Imidazole cell adhesion inhibitors discovered by Sankyo team

Oral zebularine reactivates silenced genes, inhibits DNA methylation

Takeda plans two trials of Actos in heart disease

NCX-1020 enters clinical development

Ganite sNDA filing completed

Pennsaid approved in Canada

Initiation of first of two expanded phase II trials of GVAX lung cancer vaccine

Chimeric peptides show high potency in CHF in preclinical studies

Oxford BioMedica cleared to begin phase II trial of TroVax in colorectal cancer

Phase III program to assess fondaparinux in acute coronary syndromes

Statistically significant improvement in FSAD in Alista at-home study

Characterization of new CDK1/CDK2 inhibitor

FAUC-312 identified as potent and selective partial agonist at D4 receptors

Orally active triazole inhibitors of TNF-alpha production designed by P&G

Glutamate antagonists with selectivity for the ionotropic GluR5 receptor under study at NeuroSearch

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....